Drug intelligence / Profile preview

SmoothLD

Development stage: Unknown
Lead developer: Voyageur Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SmoothLD is a low-density barium sulfate suspension (60% w/v) developed by Voyageur Pharmaceuticals as a diagnostic contrast agent for gastrointestinal (GI) tract imaging. Indicated for use in CT imaging and fluoroscopy, the agent is administered orally to provide radiodensity that outlines the lumen of the GI tract, facilitating the visualization of anatomical structures and potential pathologies. Unlike many synthetic barium products, SmoothLD is produced using pharmaceutical-grade barium sulfate sourced from Voyageur's own Frances Creek deposit in British Columbia, part of a vertically integrated production model. The product was licensed by Health Canada and scheduled for commercial distribution beginning in August 2025.

Brand names: SmoothLD
Other names: barium sulfate 60% w/v oral suspension

Beyond the preview

Go deeper on SmoothLD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SmoothLD.

Explore the full profile